---
title: "Immunovant, Inc. Stock 12‑Month Price Target Raised to $42.55, Implies 62% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287095669.md"
description: "Immunovant, Inc.'s stock price target has been raised from $40.29 to $42.55, indicating a potential upside of 62%. This estimate comes from 11 analysts, with price forecasts ranging from $23 to $66 per share. The consensus rating remains a 'Buy' with 8 Buys, 4 Holds, and no Sells."
datetime: "2026-05-20T16:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287095669.md)
  - [en](https://longbridge.com/en/news/287095669.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287095669.md)
---

# Immunovant, Inc. Stock 12‑Month Price Target Raised to $42.55, Implies 62% Upside

-   According to estimates from 11 analysts, Immunovant, Inc. stock's average price target has risen from $40.29 to $42.55, with forecasts ranging from $23 to $66 per share
-   Based on the May 19 closing price, the updated target implies approximately 62% potential upside
-   Consensus rating remains at “Buy” across 12 covering analysts, with 8 Buys, 4 Holds and 0 Sells

Explore more price target data and ratings for Immunovant, Inc. on the , and track all previous and future analyst recommendations for Immunovant, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [IMVT.US](https://longbridge.com/en/quote/IMVT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [These Analysts Increase Their Forecasts On Immunovant After Q4 Results](https://longbridge.com/en/news/287250728.md)
- [Assessing Immunovant (IMVT) Valuation After Strong IMVT-1402 Data And Refocused Pipeline Strategy](https://longbridge.com/en/news/287221923.md)
- [Capstone Companies, Inc. announces Execution of Binding Letter of Intent with eBliss Global, Inc. | CAPC Stock News](https://longbridge.com/en/news/286782166.md)
- [Immunovant Posts Wider FY26 Loss, Advances IMVT-1402 Pipeline; Stock Up](https://longbridge.com/en/news/287065251.md)
- [Immunovant reports $147.9M quarterly net loss, $902.1M cash as of Mar 31, 2026](https://longbridge.com/en/news/287056202.md)